

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

GIST882

RRID:CVCL_7044

Type: Cell Line

Proper Citation

RRID:CVCL_7044

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7044

Proper Citation: RRID:CVCL_7044

Description: Cell line GIST882 is a Cancer cell line with a species of origin Homo sapiens (Human)

Disease: Gastrointestinal stromal tumor

Defining Citation: [PMID:11526490](#), [PMID:16077968](#), [PMID:16982758](#), [PMID:19706776](#), [PMID:25239608](#), [PMID:29866822](#), [PMID:30488756](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: GIST882

Synonyms: GIST-882, GIST 882

Cross References: EFO:EFO_0022342, cancercellines:CVCL_7044, ChEMBL-Cells:ChEMBL4513108, ChEMBL-Targets:ChEMBL4513126, Cosmic:1180672, Cosmic:1217560, Cosmic:1244759, Cosmic:1477623, Cosmic:1873949, Cosmic:2805389, GEO:GSM486234, GEO:GSM2527254, GEO:GSM2527255, GEO:GSM2786738, Lonza:694, Progenetix:CVCL_7044, PubChem_Cell_line:CVCL_7044, Wikidata:Q54835862

ID: CVCL_7044

Record Creation Time: 20220427T215902+0000

Record Last Update: 20260815T232841+0000

Ratings and Alerts

No rating or validation information has been found for GIST882.

No alerts have been found for GIST882.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang CC, et al. (2026) Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST). International journal of cancer, 159(3), 797.

Ravegnini G, et al. (2026) Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs). Journal of experimental & clinical cancer research : CR, 45(1).

Sun X, et al. (2026) Long Non-Coding RNA CTD-2245E15.3 Drives Proliferation and Migration in Gastrointestinal Stromal Tumors. Biomedicines, 14(3).

Toivanen K, et al. (2023) PDE3A Is a Highly Expressed Therapy Target in Myxoid Liposarcoma. Cancers, 15(22).

Hemming ML, et al. (2022) MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer discovery, 12(7), 1804.

Yebra M, et al. (2022) Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(1), 187.

Hemming ML, et al. (2019) Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer research, 79(5), 994.

Smith BD, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer cell, 35(5), 738.